Fractyl Health (NASDAQ:GUTS) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Fractyl Health (NASDAQ:GUTS) released its earnings results on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02), FiscalAI reports.

Fractyl Health Price Performance

Shares of GUTS stock traded down $0.02 during mid-day trading on Monday, hitting $0.68. The company had a trading volume of 1,482,402 shares, compared to its average volume of 3,386,256. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The stock’s 50 day moving average price is $0.77 and its 200-day moving average price is $0.71. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $2.44. The company has a market capitalization of $107.09 million, a P/E ratio of -0.52 and a beta of 2.32.

Insiders Place Their Bets

In related news, Director Ian Sheffield purchased 35,000 shares of Fractyl Health stock in a transaction on Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the acquisition, the director owned 35,000 shares in the company, valued at approximately $25,550. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Bradley acquired 68,493 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, with a total value of $49,999.89. Following the acquisition, the director directly owned 84,622 shares in the company, valued at approximately $61,774.06. The trade was a 424.66% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 171,493 shares of company stock worth $127,150. 8.52% of the stock is currently owned by insiders.

Institutional Trading of Fractyl Health

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in shares of Fractyl Health in the 2nd quarter valued at approximately $31,000. Scientech Research LLC bought a new position in shares of Fractyl Health during the 3rd quarter valued at approximately $49,000. Prelude Capital Management LLC purchased a new stake in Fractyl Health during the 3rd quarter valued at $55,000. Jump Financial LLC purchased a new stake in Fractyl Health during the 4th quarter valued at $57,000. Finally, Centiva Capital LP bought a new stake in Fractyl Health in the third quarter worth $78,000.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Craig Hallum initiated coverage on shares of Fractyl Health in a research report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price target for the company. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings lowered Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a report on Thursday, June 4th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Fractyl Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.12.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.